Sakditad Saowapa, Oncologist at UI Holden Comprehensive Cancer Center, shared a post on X:
“Bridging the Gap: Pirtobrutinib in treatment-naïve CLL.
The phase III BRUIN CLL-313 trial shows:
- Significant PFS benefit (24-mo PFS 93.4% vs 70.7%).
- OS advantage vs BR.
- Favorable safety profile.
A noncovalent BTKi moving earlier in the treatment paradigm.
Key question:
Will pirtobrutinib compete with frontline cBTKi or combination regimens?”
Title: Bridging the Gap: Pirtobrutinib for Treatment-Naïve Chronic Lymphatic Leukemia
Authors: Marc J. Braunstein, Michael E. Williams
Read The Full Article
Other articles about Lymphatic Leukemia on OncoDaily.